Claes Karlsson

Publications
CV
Public outreach and news

Articles

Article: NATURE CANCER. 2022;3(2):251-261
The Molecular Tumor Board Portal supports clinical decisions and automated reporting for precision oncology
Tamborero D; Dienstmann R; Rachid MH; Boekel J; Lopez-Fernandez A; Jonsson M; Razzak A; Brana I; De Petris L; Yachnin J; Baird RD; Loriot Y; Massard C; Martin-Romano P; Opdam F; Schlenk RF; Vernieri C; Masucci M; Villalobos X; Chavarria E; Balmana J; Apolone G; Caldas C; Bergh J; Ernberg I; Frohling S; Garralda E; Karlsson C; Tabernero J; Voest E; Rodon J; Lehtio J
Article: LEUKEMIA. 2019;33(4):969-980
Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma
Fraser G; Cramer P; Demirkan F; Silva RS; Grosicki S; Pristupa A; Janssens A; Mayer J; Bartlett NL; Dilhuydy M-S; Pylypenko H; Loscertales J; Avigdor A; Rule S; Villa D; Samoilova O; Panagiotidis P; Goy A; Pavlovsky MA; Karlsson C; Hallek M; Mahler M; Salman M; Sun S; Phelps C; Balasubramanian S; Howes A; Chanan-Khan A
Article: HAEMATOLOGICA. 2019;104(4):797-804
FFirst-line therapy in chronic lymphocytic leukemia: a Swedish nation-wide real-world study on 1053 consecutive patients treated between 2007 and 2013
Sylvan SE; Asklid A; Johansson H; Klintman J; Bjellvi J; Tolvgard S; Kimby E; Norin S; Andersson P-O; Karlsson C; Karlsson K; Lauri B; Mattsson M; Sandstedt AB; Strandberg M; Osterborg A; Hansson L
Article: HAEMATOLOGICA. 2016;101(12):1573-1580
Real-world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: data from 95 consecutive patients treated in a compassionate use program. A study from the Swedish Chronic Lymphocytic Leukemia Group
Winqvist M; Asklid A; Andersson PO; Karlsson K; Karlsson C; Lauri B; Lundin J; Mattsson M; Norin S; Sandstedt A; Hansson L; Osterborg A
Article: THE LANCET ONCOLOGY. 2016;17(2):200-211
Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study
Chanan-Khan A; Cramer P; Demirkan F; Fraser G; Silva RS; Grosicki S; Pristupa A; Janssens A; Mayer J; Bartlett NL; Dilhuydy M-S; Pylypenko H; Loscertales J; Avigdor A; Rule S; Villa D; Samoilova O; Panagiotidis P; Goy A; Mato A; Pavlovsky MA; Karlsson C; Mahler M; Salman M; Sun S; Phelps C; Balasubramanian S; Howes A; Hallek M; Assouline S; Bence-Bruckler I; Buckstein R; Fraser G; Larratt L; Minuk L; Villa D; Angevine A; Bartlett N; Bixby D; Caimi P; Chanan-Khan A; Craig M; Forero-Torres A; Ganguly S; Goy A; Heffner L; Hermann R; Lansigan F; Leis J; Letzer J; Link B; Liu D; McCaul K; McGuire E; Skinner W; Starodub A; Stuart R; Thirman M; Tirumali N; Yang J; Janssens A; Offner F; Van den Neste E; Van Hoof A; Mayer J; Novak J; Trneny M; Cartron G; Dartigeas C; Dilhuydy M; Ghez D; Haioun C; Leblond V; Salles G; Balser C; Cramer P; Dreger P; Durig J; Eckart M; Heinrich B; Illmer T; Jentsch-Ullrich K; Pfreundschuh M; Schetelig J; Schlag R; Soling U; Stilgenbaue S; Anagnostopoulos A; Dimopoulos A; Panagiotidis P; Vrakidou E; Bairey O; Ben Yehuda D; Braester A; Fineman R; Herishanu Y; Nagler A; Ruchlemer R; Tadmor T; Grosicki S; Homenda W; Jurczak W; Pluta A; Woszczyk D; Espirito Santo A; Luis R; Raposo J; Viveiros C; Alexeeva J; Dunaev Y; Golubeva M; Khuageva N; Loginov A; Lysenko I; Osmanov E; Pavlov V; Pristupa A; Proydakov A; Rossiev V; Samarina I; Samoilova O; Serduk O; Shneider T; Udovitsa D; Voloshin S; Gayoso J; Gonzalez M; Gonzalez Barca E; Hernandez Rivas J; Jargue I; Loscertales J; Karlsson C; Sender M; Aktan M; Arslan O; Demirkan F; Ferhanoglu B; Kaynar L; Sayinalp N; Vaural F; Yagci M; Dyagil I; Kaplan P; Masliak Z; Oliynyk H; Popovska T; Pylypenko H; Rekhtman G; Dearden C; Morley N; Moss P; Rule S; Pavlovsky M; Riveros D; Santucci-Silva R; Romeo M; Scheliga A; Salazar L; Gomez D; Ramirez E; Jung C
Article: ANNALS OF HEMATOLOGY. 2014;93(10):1725-1733
Alemtuzumab (anti-CD52 monoclonal antibody) as single-agent therapy in patients with relapsed/refractory chronic lymphocytic leukaemia (CLL)-a single region experience on consecutive patients
Sylvan SE; Lundin J; Ipek M; Palma M; Karlsson C; Hansson L
Article: LEUKEMIA AND LYMPHOMA. 2014;55(8):1774-1780
Outcomes of patients with fludarabine-refractory chronic lymphocytic leukemia: a population-based study from a well-defined geographic region
Sylvan SE; Hansson L; Karlsson C; Norin S; Lundin J; Osterborg A
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2009;144(1):78-85
Phase II study of subcutaneous alemtuzumab without dose escalation in patients with advanced-stage, relapsed chronic lymphocytic leukaemia
Karlsson C; Lundin J; Kimby E; Kennedy B; Moreton P; Hillmen P; Osterborg A
Article: LEUKEMIA. 2007;21(3):511-514
Treatment of severe refractory autoimmune hemolytic anemia in B-cell chronic lymphocytic leukemia with alemtuzumab (humanized CD52 monoclonal antibody)
Karlsson C; Hansson L; Celsing F; Lundin J
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2006;135(4):475-485
Reconstitution of the T-cell repertoire following treatment with alemtuzumab (anti-CD52 monoclonal antibody) in patients with B-cell chronic lymphocytic leukaemia
Rezvany MR; Tehrani MJ; Karlsson C; Lundin J; Rabbani H; Osterborg A; Mellstedt H
Article: LEUKEMIA. 2004;18(3):484-490
Cellular immune reconstitution after subcutaneous alemtuzumab (anti-CD52 monoclonal antibody, CAMPATH-1H) treatment as first-line therapy for B-cell chronic lymphocytic leukaemia
Lundin J; Porwit-MacDonald A; Rossmann ED; Karlsson C; Edman P; Rezvany MR; Kimby E; Österborg A; Mellstedt H

All other publications

Letter: ACTA ONCOLOGICA. 2023;62(6):560-564
The BioLymph study - implementing precision medicine approaches in lymphoma diagnostics, treatment and follow-up: feasibility and first results
Smedby KE; Waesterlid T; Tham E; Haider Z; Joelsson J; Thorvaldsdottir B; Krstic A; Wahlin BE; Foroughi-Asl H; Karlsson C; Eloranta S; Saft L; Palma M; Kwiecinska A; Hansson L; Osterborg A; Wirta V; Rassidakis G; Sander B; Sonnevi K; Rosenquist R
Corrigendum: NATURE CANCER. 2022;3(5):649
The Molecular Tumor Board Portal supports clinical decisions and automated reporting for precision oncology (vol 3, pg 251, 2022)
Tamborero D; Dienstmann R; Rachid MH; Boekel J; Lopez-Fernandez A; Jonsson M; Razzak A; Brana I; De Petris L; Yachnin J; Baird RD; Loriot Y; Massard C; Martin-Romano P; Opdam F; Schlenk RF; Vernieri C; Masucci M; Villalobos X; Chavarria E; Balmana J; Apolone G; Caldas C; Bergh J; Ernberg I; Frohling S; Garralda E; Karlsson C; Tabernero J; Voest E; Rodon J; Lehtio J
Letter: NATURE MEDICINE. 2020;26(7):992-994
Support systems to guide clinical decision-making in precision oncology: The Cancer Core Europe Molecular Tumor Board Portal
Tamborero D; Dienstmann R; Rachid MH; Boekel J; Baird R; Brana I; De Petris L; Yachnin J; Massard C; Opdam FL; Schlenk R; Vernieri C; Garralda E; Masucci M; Villalobos X; Chavarria E; Calvo F; Frohling S; Eggermont A; Apolone G; Voest EE; Caldas C; Tabernero J; Ernberg I; Rodon J; Lehtio J
Letter: HAEMATOLOGICA. 2019;104(5):E208-E210
Long-term real-world results of ibrutinib therapy in patients with relapsed or refractory chronic lymphocytic leukemia: 30-month follow up of the Swedish compassionate use cohort
Winqvist M; Andersson P-O; Asklid A; Karlsson K; Karlsson C; Lauri B; Lundin J; Mattsson M; Norin S; Sandstedt A; Rosenquist R; Spath F; Hansson L; Osterborg A
Meeting abstract: BLOOD. 2015;126(23):1745
Real-World Results on Ibrutinib in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL): Data from 97 Swedish Patients Treated in a Compassionate Use Program
Hansson L; Winqvist M; Asklid A; Andersson P-O; Karlsson K; Karlsson C; Lauri B; Lundin J; Mattsson M; Norin S; Sandstedt A; Osterborg A
Letter: BRITISH JOURNAL OF HAEMATOLOGY. 2012;159(5):608-612
Phase I study of lenalidomide and alemtuzumab in refractory chronic lymphocytic leukaemia: maintaining immune functions during therapy-induced immunosuppression
Sylvan SE; Rossmann E; Mozaffari F; Porwit A; Norin S; Karlsson C; Hansson L; Lundin J; Osterborg A
Letter: BLOOD CANCER JOURNAL. 2011;1(6):e22
Virus reactivations and serology patterns following first-line therapy with alemtuzumab or fludarabine-based combination therapy in patients with chronic lymphocytic leukemia
Karlsson C; Dahl H; Lundin J; Rossmann E; Brytting M; Mellstedt H; Linde A; Osterborg A
Thesis / dissertation: 2010
Targeted monoclonal antibody therapy in chronic lymphocytic leukemia
Karlsson, Claes
Review: CURRENT HEMATOLOGIC MALIGNANCY REPORTS. 2009;4(1):47-53
Alemtuzumab to treat refractory autoimmune hemolytic anemia or thrombocytopenia in chronic lymphocytic leukemia.
Osterborg A; Karlsson C; Lundin J
Letter: LEUKEMIA. 2006;20(12):2204-2007
Alemtuzumab as first-line therapy for B-cell chronic lymphocytic leukemia:: long-term follow-up of clinical effects, infectious complications and risk of Richter transformation
Karlsson C; Norin S; Kimby E; Sander B; MacDonald AP; Nilsson B; Johansson E; Mellstedt H; Lundin J; Osterborg A
Editorial comment: MEDICAL ONCOLOGY. 2006;23(1):137-139
Alemtuzumab therapy for severe autoimmune hemolysis in a patient with B-cell chronic lymphocytic leukemia
Lundin J; Karlsson C; Celsing F
Meeting abstract: BLOOD. 2004;104(11):277A
Virus reactivation profile as assessed by PCR and serology pattern following first-line alemtuzumab (anti-CD52 monoclonal antibody, Campath®) therapy in patients with B-CLL.
Karlsson C; Dahl H; Linde A; Lundin J; Björkholm M; Mellstedt H; Osterborg A

Employments

Affiliated to Research, Department of Oncology-Pathology, Karolinska Institutet, 2024-2027

Degrees and Education

Degree Of Doctor Of Philosophy, Department of Oncology-Pathology, Karolinska Institutet, 2010
University Medical Degree, Karolinska Institutet, 1994

Articles

All other publications

Employments

Degrees and Education

News from KI

Events from KI